Prometheus Laboratories
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
Palmetto Releases Draft Coverage Determinations for Several Molecular Diagnostics
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
Citing Validation Costs, IP Concerns, Reference Labs Offer Gloomy Take on Protein Biomarker Tests
Premium
VANCOUVER, BC – At the American Society for Mass Spectrometry annual meeting here this week a number of major vendors reiterated their commitment to moving their instruments into the clinic (
Shares of Rosetta Genomics got a major boost this week after the company effected a one-for-fifteen reverse stock split, and then announced it had launched a new microRNA-based diagnostic and had obtained Medicare coverage for its flagship cancer of unknown primary origin microRN
The University of California of Oakland has received US Patent No. 8,162,555, "Printing pins having selective wettability and method of making same." Printing pins are described that have an exterior surface and an interior surface that defines a lumen or capillary tract.
Mar 20, 2012
Supreme Court Strikes Down Prometheus Patents
Dec 1, 2011
May 24, 2011
Nestle Health Science Buying Prometheus Laboratories
Apr 7, 2011
Dec 10, 2010
Prometheus Labs, UCLA Collaborate on IBD Markers
Sep 9, 2010